Overview of precision oncology trials: challenges and opportunities
- 3 August 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 11 (8) , 797-804
Abstract
Introduction: In recent years, the therapeutic management of selected patients with cancer has shifted toward the ‘precision medicine’ approach based on patient’s mechanisms of tumorigenesis, and their baseline characteristics and comorbidities. Complete tumor and cell-free DNA profiling using next-generation sequencing, proteomic and RNA analysis, and immune mechanisms should to be taken into consideration and accurate bioinformatic analysis is essential to optimize patient’s treatment. Areas covered: The challenges and opportunities of conducting clinical trials in precision oncology are summarized. Expert commentary: Precision medicine has significantly changed the diagnostic and therapeutic landscape of cancer. Successful implementation of precision medicine requires translational and bioinformatics infrastructure to support optimization of treatment selection. Targeted therapy, immunotherapy, T-cell therapy alone or in combination with cytotoxic or other effective therapeutic strategies and innovative clinical trials with adaptive design should be offered to all patients. Data sharing and ‘N-of-1’ models hold the promise to optimize the treatment of individual patients and expedite drug approval for rare alterations and tumor types. Artificial intelligence will facilitate accurate utilization of sequencing data to perform algorithm analysis. Collaboration of healthcare providers with pharmaceutical and biotechnical companies, scientific organizations, and governmental regulatory agencies have a crucial role in curing cancer.Keywords
Funding Information
- National Institutes of Health (P30 CA016672)
This publication has 52 references indexed in Scilit:
- Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for CancerJNCI: Journal of the National Cancer Institute, 2012
- Raise standards for preclinical cancer researchNature, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Adjuvant Trastuzumab in HER2-Positive Breast CancerNew England Journal of Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory CancersJournal of Clinical Oncology, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Addiction to Oncogenes--the Achilles Heal of CancerScience, 2002
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990